villafan1
08 Nov 2016
Re: Good Motley Fool review. Another article today, which gives an explanation for the recent falls... [link]
Openwoe
08 Nov 2016
Re: Good Motley Fool review. Fred - Just one question about your manipulation conspiracy theory. If for some reason the share price has been driven artificially low, why has this not attracted other investors who may have no current position to buy in at an undervalued price? I assume the market price is free floating and reflects the usual forces of supply & demand. Many thanks.
Hardboy
08 Nov 2016
Re: Good Motley Fool review. And even more luck to you, Fred.I do not see any way in which I can assist your crusade, but if there is, please let me know.
Fred Prior
08 Nov 2016
Re: Good Motley Fool review. It's as though all commentators are blind to Hikma's price movement.---------- ---------- --------hard boy, you have been around a while and I am sure you are fighting with your inner self, your "logical" side, to admit to yourself that markets are manipulated to suit that of the big boys, if their is wealth to be garnered from a stocks movement, they will make sure it is moved, be that to the detriment or fortune of us mere spectators in this circus comes down to being on the "right side" of the trade, it would appear that after the huge director and chairman buying in Hikam, people assumed they would be on the right side of the trade, yet the price at the top of the screen since tells a different story.Its about time the UK found out exactly what goes on in this corrupted finical circus of the so called markets.A guy selling knocked off goods at a Sunday market has more morals than any employee at any financial institution in the City thats for sure.Do not fret, all will and all is going to be revealed soon, people will stand up and take notice when FP tells all, of that you can be assured. When the so called FCA do nothing about it, then somebody has to take a stand to rid the vermin of feeding off the unsuspected any longer.They may laugh now reading this post but it will be I that laugh last and will certainly laugh longest when that day cometh.Good luck hardboy.Regards
Hardboy
08 Nov 2016
Re: Good Motley Fool review. This MF article is a great example of the financial press' myopia. he had a story he wanted to cover, and the fact that 2 companies involved in the story both fell on a particular day fitted the story; but the smallest bit of further research would have told him that "Hikma Pharmaceuticals and Shire fell heavily on Friday," is a stupid comment. Relative to recent daily moves, neither share's performance on Friday could be described as "heavy."At least he noticed Hikma's huge drop over recent months, but put it purely down to the interims. When a company's announcement includes forwarded looking statements which depress the market, the share price tends to react sharply for a couple of days, then drift. That is not what has been happening here. It's as though all commentators are blind to Hikma's price movement.
middler2
08 Nov 2016
Good Motley Fool review. This popped into my inbox today. I have omitted the comments on Shire.Shares of FTSE 100 drug-makers Hikma Pharmaceuticals (LSE: HIK) and Shire(LSE: SHP) fell heavily on Friday, following a report that the US Department of Justice could bring criminal charges against generic manufacturers as part of an investigation into suspected price collusion.What does this news mean for Hikma and Shire? Should you ditch these stocks right now or is this a good opportunity to buy?UncertaintyA story by Bloomberg, sourced from "people familiar with the matter", said that the Justice Department's antitrust investigation, which began two years ago, "now spans more than a dozen companies and about two dozen drugs".Hikma was not among the 12 companies named by Bloomberg, which included industry giants Mylan and Teva Pharmaceutical Industries, but the Footsie firm is the number six generics company in the US. Furthermore, it is a manufacturer of two drugs referred to in the Bloomberg story -- doxycycline and digoxin -- although, according to the Financial Times: "Analysts said the two medicines are now relatively unimportant to Hikma's US generics division".Hikma may or may not be drawn into the investigation, but in any case antitrust inquiries are fairly common and when fines are levied they represent a one-off hit and rarely lead to any lasting damage to a company.Long-term valueI'm more interested in Hikma's long-term prospects and current valuation after a 6.8% fall in its shares on Friday. In fact, at 1,620p, the shares -- now down 40% since August when the company downgraded current-year earnings guidance -- are at a two-year low.As far as prospects are concerned, I believe Hikma has a bright future. The group generates 60% of its revenue from the US, while 34% comes from the Middle East and North Africa, which is an attractive region for high, long-term growth. The business is also nicely diversified across generics (30%), branded (30%) and injectables (40%).As far as valuation is concerned, 2016's depressed earnings represent a bit of short-term indigestion as a result of a major acquisition. Looking ahead to 2017, and cautiously taking earnings forecasts from the lower end of analyst expectations (110p versus a consensus of 125p), we get a price-to-earnings (P/E) ratio of 14.7 and earnings growth of 25%, giving a highly attractive P/E-to-earnings growth (PEG) ratio of 0.6.This wide margin of safety persuades me that Hikma offers excellent long-term value at the present time and I rate the shares a 'buy'.
Fred Prior
08 Nov 2016
Amazing its a blue day for Hikma after a seemingly endless torrent of red! I would assume bottomed out on the equalling of the yearly low and shorts will now start to cover in advance of the trading update this week.I am a little disappointed it did not reach 1500p as I had made provisions last night to transfer a decent amount of funds into my broker account and go shopping this morning, perhaps my buy order @ 1500p scared them off a wee bit.Oh well, not a lot to get exited about here as even another 20% rise from here barely puts recent buyers back level but thats what they want, they want to condition a spread betters mind that at the first opportunity they will close out their position either at a loss or no profit.It really is a game for fools and horses.Lets hope they take it down some more later and that my disappointment will turn to joy as this is a good divi payer and highly undervalued , opt at least the insiders of Hikma seem to think so......
middler2
07 Nov 2016
Strange tades - can anyone explain? On level 2 there were some very strange trades at strange prices after close today. Can anyone explain for me please?The uncrossing trade of 232K or so was at 16.35 and for 1641p.Thereafter there were 5 g trades (negotiated, so they should not have happened after close). Three were about 1641, but two were at 1614 (59 shares) and 1631 (1447 shares). In addition there were 5 I trades (OTC immediately declareable?) Two were at 1642, but two others were 1624.This may well be ignorance on my part, but does not look rightFor what it is worth, I stick by my belief that as generic manufacturers , they would find it hard to fix prices and the results this week will be good, so I am still buying.
Fred Prior
07 Nov 2016
The manipulation continues as duly promised I managed to get it out in the press on Friday, so more people are aware of Hikma, we spoke at length about my info re certain institutions that I believe are instigators in the manipulation and artificial price movements on Hikma and shares in general, however they said before they would run such an article, I need to sit with one of their lawyers to make sure we are not infringing anyones rights. The jouno was very exited by the fact he could be running a huge in-depth spread about manipulation in the markets and by whom, as he said he has not done this kind of story before, I told him it will be the first and last and will hopefully severely reduce the client footfall and new accounts opened as ALL people will be made aware of the manipulation and revelations of what really goes on when you open a spread bet account........It will be a defining moment for FP thats for sure, those that laugh last an all that eh!I instructed my broker to buy a modest tranche @ 1500p should the opportunity arise.FTSE up, sector up, Hikma down, theres a surprise not?Results this week, I would expect some headwinds in the currency department but hopefully product sales should be firing on all four.
bamboozled
06 Nov 2016
Re: share price s9 : think you need to read the previous posts to keep up!!!Saturday Telegraph says:"Hikma slumped to an eight month low after HSBC warned that the US Department of Justice investigation into alleged generic drug price collusion " may include Hikma in due course". Analysts slashed the FTSE 100 company's target price from £25.25 to £19.85 but retained its "hold" rating. The bank thinks all generics companies are likely to be "under suspicion".Other pharma companies have already submitted subpoenas and although HSBC does not believe this included Hikma it thinks the group 's share price could come under pressure until there is more clarity on the scope and breadth of the investigation.Steve McGarry,of HSBC, said, "In our view,investors are unlikely to give any generics company the benefit of the doubt and may assume that there may be a reason for the DoJ to target all generics comapnies in due course". Meanwhile ,broker Numis slashed its target price to £23.50 but lifted its rating to "hold" from "buy" as it believes the third quarter results, due for release next week, will be a catalyst for a re-rating.Shares tumbled 119p,or 6.8pc,to £26.26."Talk about stating the blinkin obvious, the shares have been in decline for weeks( and somebody knew)!!
susanne9
04 Nov 2016
share price On GSK discussion board there is posting re the US decision to probe into the possible collusion amongst the pharmas on price-fixing for certain drugs. Could this not be partly responsible for the drop in SP? It is odd that there is still no mention in the press about dodgy dealings in the Hikma camp.
Ravinell
04 Nov 2016
Re: Ravinell I'm sorry you take such umbrage at my post. Harsh? In light of your response it is very reasonable by comparison. I just hope for your sake your market analysis is better than your invective.
bamboozled
04 Nov 2016
Re: Yippeee new yearly low reached Hardboy: "Generally you are right, markets will likely face a big sell off if Trump wins, but the recent decline in the Pharma Sector is in fear of a Clinton Victory, so Hikma may be spared the sell off if that happens. "I dunno, I 'm sure I read somewhere that Trump had the same idea as Clinton wrt bringing pharma cost down. Anyway I think this is going down again next week and I'll need to decide whether to buy more on the weakness or just sit on my hands and give it time.So much for defensive pharma stocks!
Hardboy
04 Nov 2016
Re: Yippeee new yearly low reached Apologies - well spotted. Should have been US of course.
velocipede
04 Nov 2016
Re: Yippeee new yearly low reached "I heard a good explanation of the choice for American Voters recently: Some one who represents all that is wrong with UK culture or someone who represents all that is wrong with US Politics. "Was that a Freudian strip? Sorry slip?
